704 related articles for article (PubMed ID: 26937492)
1. Olaparib for the treatment of ovarian cancer.
Bornstein E; Jimeno A
Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
[TBL] [Abstract][Full Text] [Related]
2. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
3. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
Nirsimloo R; Gourley C
Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428
[TBL] [Abstract][Full Text] [Related]
5. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
6. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
7. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
8. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
9. Olaparib (Lynparza) for advanced ovarian cancer.
Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
[No Abstract] [Full Text] [Related]
10. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
[TBL] [Abstract][Full Text] [Related]
11. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
12. Olaparib for the treatment of epithelial ovarian cancer.
McLachlan J; Banerjee S
Expert Opin Pharmacother; 2016; 17(7):995-1003. PubMed ID: 26967466
[TBL] [Abstract][Full Text] [Related]
13. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
Frampton JE
BioDrugs; 2015 Apr; 29(2):143-50. PubMed ID: 25899311
[TBL] [Abstract][Full Text] [Related]
14. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
15. Olaparib.
Goulooze SC; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2016 Jan; 81(1):171-3. PubMed ID: 26344419
[TBL] [Abstract][Full Text] [Related]
16. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
Chen Y; Du H
Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Kim G; Ison G; McKee AE; Zhang H; Tang S; Gwise T; Sridhara R; Lee E; Tzou A; Philip R; Chiu HJ; Ricks TK; Palmby T; Russell AM; Ladouceur G; Pfuma E; Li H; Zhao L; Liu Q; Venugopal R; Ibrahim A; Pazdur R
Clin Cancer Res; 2015 Oct; 21(19):4257-61. PubMed ID: 26187614
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM; Aghajanian C; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Loman N; Robertson JD; Mann H; Kaufman B
Gynecol Oncol; 2016 Feb; 140(2):199-203. PubMed ID: 26723501
[TBL] [Abstract][Full Text] [Related]
19. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
